Long-term bisphosphonates use and atypical femoral fracture

Year 2024, Volume: 49 Issue: 1, 235 - 238, 29.03.2024

Gaukhar Bakhtiyarova Mehtap Tınazlı Deniz Aydın

https://doi.org/10.17826/cumj.1353368

Abstract

Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration, increasing the risk of fractures. As the global incidence of osteoporosis rises, it has become a pressing concern for healthcare professionals. Long-term use of bisphosphonates (BPs), commonly prescribed for osteoporosis, has been associated with atypical femur fractures (AFFs). While AFFs are relatively rare, they are a serious concern due to their potential complications.

Keywords

biphosphonate, osteoporosis, femur fracture

Ethical Statement

31.08.2023 Ethics Committee Approval As requested by Cukurova Medical Journal, Ethics Committee Approval is not necessary for letter to editor or referral articles. Thank you for your time and assistance. Sincerly, Gaukhar Bakhtiyarova Mehtap Tınazlı Deniz Aydın

Supporting Institution

Near East University

Project Number

1

Thanks

I thank my colleagues for writing this material, and I also want to thank the Editorial Board for their attention to our work and the opportunity to publish ...

Uzun süreli bisfosfonat kullanımı ve atipik femur kırığı

Abstract

Osteoporoz, düşük kemik kütlesi ve mikro mimari bozulma ile karakterize, kırık riskini artıran sistemik bir iskelet bozukluğudur. Osteoporozun küresel insidansı arttıkça, sağlık profesyonelleri için acil bir endişe kaynağı haline gelmiştir. Osteoporoz için yaygın olarak reçete edilen bifosfonatların (BP'ler) uzun süreli kullanımı atipik femur kırıkları (AFF'ler) ile ilişkilendirilmiştir. AFF'ler nispeten nadir görülmekle birlikte, potansiyel komplikasyonları nedeniyle ciddi bir endişe kaynağıdır.

Keywords

bigosofonat, femur kırığı, osteoporoz

Project Number

1

References

• Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3-44.
• Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1-23.
• Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172:930–6.
• Kang JS, Won YY, Kim JO, Min BW, Lee KH, Park KK et al. Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study. Int Orthop. 2014;38:1247-53.
• Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-94.
• Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28:63-82.
• Aspenberg P, Genant HK, Johansson T, Nino AJ, See K et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Mineral Res. 2010;25:404-14.
• Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921-6.
• Black DM, Geiger EJ, Eastell R et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383:743–53.
• Hwang S, Seo M, Lim D, Choi MS, Park JW, Nam K. Bilateral atypical femoral fractures after bisphosphonate treatment for osteoporosis: a literature review. J Clin Med. 2023;12:1038.